Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO-25-01020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy.
Cancer Discov
August 2025
Dana-Farber Cancer Institute, Boston, MA, United States.
EGFR tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes for EGFR-mutated non-small cell lung cancer (NSCLC) patients, but relapse frequently occurs due to drug tolerant persister (DTP) cells that can evolve and develop diverse mechanisms of drug resistance. In samples from patients with EGFR-mutated NSCLC treated with EGFR-TKIs in the neoadjuvant setting, we observed enriched expression of the cell surface protein TROP2, a target of clinically active antibody drug conjugates (ADCs). We confirmed these findings across multiple EGFR-mutated NSCLC cell line and patient-derived xenograft models treated with osimertinib in vivo.
View Article and Find Full Text PDFNeoadjuvant Osimertinib for Resectable -Mutated Non-Small Cell Lung Cancer.
J Clin Oncol
September 2025
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose: Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor ()-mutated non-small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes.
Methods: In this randomized, controlled, phase III study, patients with resectable, -mutated, stage II-IIIB NSCLC were randomly assigned (1:1:1) to receive neoadjuvant osimertinib (80 mg orally once daily for ≥9 weeks) plus platinum-based chemotherapy (once every 3 weeks for three cycles), osimertinib monotherapy (for ≥9 weeks), or placebo plus platinum-based chemotherapy (control), followed by surgical resection.
Neoadjuvant Osimertinib: A Step Ahead or Just a Step?
J Clin Oncol
September 2025
Duke Cancer Institute, Duke University School of Medicine, Durham, NC.
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee.
J Thorac Oncol
August 2025
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. Electronic address:
Precision oncology has transformed the management of NSCLC by tailoring treatment to the specific genetic alterations driving oncogenesis. Targeted therapies, such as tyrosine kinase inhibitors, have been found to dramatically improve survival in patients with advanced-stage NSCLC. However, treatment options remain limited for patients with early or locally advanced stage (I-III) NSCLC harboring driver mutations, when the disease is not resectable, or the patient is unsuitable for surgery due to poor fitness or comorbidities.
View Article and Find Full Text PDFAdvancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?
J Thorac Oncol
May 2025
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.